AB Science is a dynamic pharmaceutical company dedicated to discovering, developing, and commercializing innovative protein kinase inhibitors (PKIs). These targeted therapies are designed to address unmet medical needs in human health, particularly in oncology, inflammatory diseases, and central nervous system disorders, as well as in veterinary medicine. The company's lead compound, masitinib, has shown promise in various indications. AB Science focuses on a science-driven approach to bring novel treatments to patients and animals worldwide.
Serves as the central hub for AB Science's global operations, including strategic management, research and development oversight, corporate finance, and investor relations.
Located in the prestigious 8th arrondissement of Paris, known for its proximity to major business centers and landmarks. The office space is designed to support advanced research coordination and corporate activities within a classic Parisian architectural setting.
Characterized by a strong focus on scientific innovation, rigorous research methodologies, collaboration, and a commitment to advancing medical treatments. The environment fosters expertise and dedication among its highly specialized team.
The Paris headquarters is pivotal for AB Science, anchoring its French origins and its position within the European pharmaceutical landscape. It facilitates strategic decision-making, R&D direction, and engagement with European regulatory bodies and research institutions.
AB Science operates with a global outlook, managed from its Paris headquarters and supported by its U.S. subsidiary in New Jersey. The company's primary global footprint is through its extensive clinical trial programs, which are conducted across numerous countries in Europe, North America, and other key regions. This involves collaboration with international research institutions, hospitals, and contract research organizations (CROs) to advance its portfolio of protein kinase inhibitors for both human and veterinary applications worldwide.
3 Avenue George V
Paris
Île-de-France
France
Address: 55 Madison Avenue, Suite 400, Morristown, NJ 07960, USA (AB Science USA, L.L.C.)
To facilitate the progression of clinical trials in North America, engage with U.S. regulatory authorities, and explore strategic partnerships and commercialization opportunities in the region.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, AB Science' leadership includes:
AB Science has been backed by several prominent investors over the years, including:
No major publicly announced new hires or exits within the core executive team (e.g., CEO, CFO) of AB Science have been identified in the last 12 months (June 2023 - June 2024). The company's senior leadership has shown considerable stability.
Discover the tools AB Science uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
AB Science likely utilizes common corporate email formats. A frequently observed pattern for companies of this nature is the first initial followed by the last name, or first name separated by a dot from the last name. General inquiries can usually be directed to a generic contact email.
f[last]@ab-science.com (e.g., jdoe@ab-science.com) or [first].[last]@ab-science.com (e.g., jane.doe@ab-science.com). The general contact email is contact@ab-science.com.
Format
amoussy@ab-science.com (example based on a common format for Alain Moussy)
Example
75%
Success rate
AB Science Press Release • May 28, 2024
AB Science reported that its Phase III study (AB21004) assessing masitinib in patients with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive multiple sclerosis (nSPMS) successfully met its primary endpoint, demonstrating a statistically significant reduction in disability progression as measured by EDSS....more
AB Science Press Release • April 26, 2024
AB Science released its financial results for the full year 2023, detailing operating expenses of €13.6 million, a net loss of €14.0 million, and a cash position of €6.0 million. The company also provided updates on its ongoing clinical development programs for masitinib....more
AB Science Press Release • December 19, 2023
The company announced positive outcomes from its confirmatory Phase 3 study (AB15003), indicating that masitinib in combination with docetaxel significantly improved overall survival by 4.9 months versus placebo plus docetaxel in patients with metastatic castrate resistant prostate cancer (mCRPC) eligible for docetaxel....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including AB Science, are just a search away.